Skip to content
10-Q

Quarterly Report

PROPANC BIOPHARMA, INC. PPCB

0001493152-25-023213

← back to feed
Filed
Nov 14, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Nov 13, 2025 13.36M sh
Shares Diluted Q1 2026 · Sep 30, 2025 12.33M sh
Shares Diluted restated Q1 2026 · Sep 30, 2024 9.85K sh
Capex Q1 2026 · Sep 30, 2025 $2.49K
Operating Cash Flow Q1 2026 · Sep 30, 2025 −$1.94M
Operating Cash Flow Q1 2026 · Sep 30, 2024 −$235.52K
Long Term Debt Q1 2026 · Sep 30, 2025 $106.97K
Long Term Debt Q1 2026 · Jun 30, 2025 $537.92K
Stockholders Equity Q1 2026 · Sep 30, 2025 $14.36M
Stockholders Equity Q1 2026 · Jun 30, 2025 $13.91M
Stockholders Equity Q1 2026 · Sep 30, 2024 −$4.11M
Stockholders Equity Q1 2026 · Jun 30, 2024 −$3.78M
Current Liabilities Q1 2026 · Sep 30, 2025 $3.57M
Current Liabilities Q1 2026 · Jun 30, 2025 $5.58M
Total Liabilities Q1 2026 · Sep 30, 2025 $3.61M
Total Liabilities Q1 2026 · Jun 30, 2025 $5.73M
Current Assets Q1 2026 · Sep 30, 2025 $8.76M
Current Assets Q1 2026 · Jun 30, 2025 $8.35M
Total Assets Q1 2026 · Sep 30, 2025 $17.98M
Total Assets Q1 2026 · Jun 30, 2025 $19.63M
Eps Diluted Q1 2026 · Sep 30, 2025 −$0.39
Eps Diluted restated Q1 2026 · Sep 30, 2024 −$35.97
Eps Basic Q1 2026 · Sep 30, 2025 −$0.39
Eps Basic restated Q1 2026 · Sep 30, 2024 −$35.97
Sga Expense Q1 2026 · Sep 30, 2025 $4.6M
Sga Expense Q1 2026 · Sep 30, 2024 $220.76K
Rd Expense Q1 2026 · Sep 30, 2025 $60.2K
Rd Expense Q1 2026 · Sep 30, 2024 $61.71K
Net Income Q1 2026 · Sep 30, 2025 −$4.84M
Net Income Q1 2026 · Sep 30, 2024 −$354.31K
Operating Income Q1 2026 · Sep 30, 2025 −$4.67M
Operating Income Q1 2026 · Sep 30, 2024 −$290.79K